Azithromycin versus doxycycline for the treatment of genital chlamydia infection: A meta-Analysis of randomized controlled trials

Clinical Infectious Diseases

Volumn 59, Issue 2, 2014, Pages 193-205

  Kong, F Y S ^a   Tabrizi, S N ^b   Law, M ^c   Vodstrcil, L A ^a,b   Chen, M ^a,d   Fairley, C K ^d   Guy, R ^c   Bradshaw, C ^a,d   Hocking, J S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

Author keywords

doxycycline

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE; TINIDAZOLE; ANTIINFECTIVE AGENT;

ARTICLE; CHLAMYDIAL URETHRITIS; CINAHL; CLINICAL EVALUATION; COCHRANE LIBRARY; CONTROLLED STUDY; DIAGNOSTIC TEST; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMBASE; FEMALE; FOLLOW UP; HUMAN; MALE; MEDLINE; META ANALYSIS; MICROBIOLOGICAL PARAMETERS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; ADULT; CHLAMYDIA INFECTIONS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE TRACT INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA INFECTIONS; DOXYCYCLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCTIVE TRACT INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904014204     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu220     Document Type: Article

References (58)

1. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections. Geneva, Switzerland: WHO, 2012.
2. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Morb Mortal Wkly Rep 2010; 59(RR-12):1-116.
3. Bachmann L, Stephens J, Richey C, et al. Measured versus self-reported compliance with doxycycline therapy for chlamydia-Associated syndromes- high therapeutic success rates despite poor compliance. Sex Transm Dis. 1999; 26:272-8.
4. Lau C-Y, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: A meta-Analysis of randomized clinical trials. Sex Transm Dis. 2002; 29:497-502. (Pubitemid 35001337)
5. Horner P. The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection. Sex Transm Infect 2006; 82: 340-3. (Pubitemid 44229455)
6. Handsfield HH. Questioning azithromycin for chlamydial infection. Sex Transm Dis. 2011; 38:1028-9.
7. Walker J, Tabrizi SN, Fairley CK, et al. Chlamydia trachomatis incidence and re-infection among young women-behavioural and microbiological characteristics. PLoS One 2012; 7:e37778.
8. LaMontagne D, Baster K, Emmett L, et al. Incidence and reinfection rates of genital chlamydia infection among women aged 16 to 24 years attending general practice, family planning and genitourinary medicine clinics in England: A prospective cohort study by the chlamydia recall study advisory group. Sex Transm Infect 2007; 83:292-303. (Pubitemid 47242508)
9. Batteiger BE, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis. 2010; 201:42-51.
10. Golden MR, Whittington WLH, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676-85. (Pubitemid 40239215)
11. Horner PJ. Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: Duration of therapy may be the key to improving efficacy. Sex Transm Infect 2012; 88:154-6.
12. Sandoz KM, Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol 2010; 5:1427-42.
13. Wang S, Papp J, Stamm W, et al. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: A meeting report. J Infect Dis. 2005; 191:917-23. (Pubitemid 40349807)
14. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. PLoS Med 2009; 6:e1000097.
15. Manhart LE, Gillespie CW, Lowens MS, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: A randomized controlled trial. Clin Infect Dis. 2013; 56:934-42.
16. Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: Emphasizing emerging pathogens-A randomized clinical trial. Clin Infect Dis. 2011; 52:163-70.
17. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-Analyses. BMJ 2003; 327:557-60. (Pubitemid 37088507)
18. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: D5928.
19. Lassus A. Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J Antimicrob Chemother 1990; 25(suppl A):115-21. (Pubitemid 20043957)
20. Steingrimsson O, Olafsson JH, Thorarinsson H, et al. Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Chemother 1990; 25(suppl A): 109-14. (Pubitemid 20043956)
21. Whatley JD, Thin RN, Mumtaz G, et al. Azithromycin vs doxycycline in the treatment of non-gonococcal urethritis. Int J STD AIDS; 1991; 2:248-51.
22. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl J Med 1992; 327:921-5.
23. Nilsen A, Halsos A, Johansen A, et al. A double blind study of single dose azithromycin and doxycycline in the treatment of chlamydial urethritis in males. Genitourin Med 1992; 68:325-7.
24. Ossewaarde JM, Plantema FH, Rieffe M, et al. Efficacy of single-dose azithromycin versus doxycycline in the treatment of cervical infections caused by Chlamydia trachomatis. Eur J Clin Microbiol Infect Dis. 1992; 11:693-7.
25. Lauharanta J, Saarinen K, Mustonen MT, et al. Single-dose oral azithromycin versus seven-day doxycycline in the treatment of nongonococcal urethritis in males. J Antimicrob Chemother 1993; 31(suppl E): 177-83. (Pubitemid 23220203)
26. Lister PJ, Balechandran T, Ridgway GL, et al. Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men. J Antimicrob Chemother 1993; 31(suppl E): 185-92. (Pubitemid 23220204)
27. Hammerschlag MR, Golden NH, Oh MK, et al. Single dose of azithromycin for the treatment of genital chlamydial infections in adolescents. J Pediatr 1993; 122:961-5. (Pubitemid 23158442)
28. Steingrimsson O, Olafsson JH, Thorarinsson H, et al. Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men. Sex Transm Dis. 1994; 21:43-6.
29. Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. JAMA 1995; 274:545-9.
30. Horner M, Heller VC, Ziegler C, et al. Azithromycin in the treatment of chlamydial cervicitis and urethritis. Acta Dermatovenerol Alp Panonica Adriat 1995; 4:121-5.
31. Gruber F, Tomic D, Brajac I. Comparative trial with azithromycin and doxycycline in gonococcal and chlamydial infections in females. G Ital Dermatol Venereol 1996; 131:403-6. (Pubitemid 27032222)
32. Thorpe EM Jr, Stamm WE, Hook EW 3rd, et al. Chlamydial cervicitis and urethritis: Single dose treatment compared with doxycycline for seven days in community based practises. Genitourin Med 1996; 72:93-7. (Pubitemid 26130425)
33. Hillis SD, Coles FB, Litchfield B, et al. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings. Sex Transm Dis. 1998; 25:5-11. (Pubitemid 28023762)
34. Tan HH, Chan RK. An open label comparative study of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in males and Chlamydia trachomatis cervicitis in female sex workers in an STD clinic in Singapore. Singapore Med J 1999; 40:519-23. (Pubitemid 29441146)
35. Sendag F, Terek C, Tuncay G, et al. Single dose oral azithromycin versus seven day doxycycline in the treatment of non-gonococcal mucopurulent endocervicitis. Aust N Z J Obstet Gynaecol 2000; 40:44-7. (Pubitemid 30153938)
36. Skerk V, Schönwald S, Strapa Z, et al. Duration of clinical symptoms in female patients with acute urethral syndrome caused by Chlamydia trachomatis treated with azithromycin or doxycycline. J Chemother 2001; 13:176-81. (Pubitemid 32337027)
37. Rustomjee R, Kharsany ABM, Connolly CA, et al. A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting. J Antimicrob Chemother 2002; 49:875-8. (Pubitemid 34537655)
38. Jang D, Sellors J, Howard M, et al. Correlation between culture testing of swabs and ligase chain reaction of first void urine from patients recently treated for Chlamydia trachomatis. Sex Transm Infect 2003; 79:237-9. (Pubitemid 36723967)
39. Guven MA, Gunyeli I, Dogan M, et al. The demographic and behavioural profile of women with cervicitis infected with Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum and the comparison of two medical regimens. Arch Gynecol Obstet 2005; 272:197-200. (Pubitemid 41413987)
40. World Health Organization. Guidelines for the management of sexually transmitted infections. Geneva, Switzerland: WHO, 2003.
41. Geisler WM, Suchland RJ, Whittington WLH, et al. Quantitative culture of Chlamydia trachomatis: Relationship of inclusion-forming units produced in culture to clinical manifestations and acute inflammation in urogenital disease. J Infect Dis. 2001; 184:1350-4. (Pubitemid 33055585)
42. Eckert LO, Suchland RJ, Hawes SE, et al. Quantitative Chlamydia trachomatis cultures: Correlation of chlamydial inclusion-forming units with serovar, age, sex, and race. J Infect Dis. 2000; 182:540-4. (Pubitemid 30654823)
43. Michel C-EC, Sonnex C, Carne CA, et al. Chlamydia trachomatis load at matched anatomic sites: Implications for screening strategies. J Clin Microbiol 2007; 45:1395-402. (Pubitemid 46762389)
44. Wiggins R, Graf S, Low N, et al. Chlamydia Screening Studies Study Group. Real-time quantitative PCR to determine chlamydial load in men and women in a community setting. J Clin Microbiol 2009; 47:1824-9.
45. West SK, Munoz B, Mkocha H, et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: A longitudinal study. Lancet 2005; 366:1296-300. (Pubitemid 41416585)
46. Somani J, Bhullar VB, Workowski KA, et al. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 2000; 181:1421-7. (Pubitemid 30252548)
47. Bhengraj AR, Vardhan H, Srivastava P, et al. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy 2010; 56:371-7.
48. Jones RB, Van Der Pol B, Martin DH, et al. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis. 1990; 162:1309-15.
49. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 2003; 326:1167-70. (Pubitemid 36649048)
50. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010; 153: 158-66.
51. Dukers-Muijrers NHTM, Morré SA, Speksnijder A, et al. Chlamydia trachomatis test-of-cure cannot be based on a single highly sensitive laboratory test taken at least 3 weeks after treatment. PLoS One 2012; 7: E34108.
52. Anagrius C, Loré B, Jensen J. Treatment of Mycoplasma genitalium. Observations from a Swedish STD clinic. PLoS One 2013; 8:e61481.
53. Johnson RB. The role of azalide antibiotics in the treatment of chlamydia. Am J Obstet Gynecol 1991;164(6 pt 2):1794-6.
54. Cerin A, Grillner L, Persson E. Chlamydia test monitoring during therapy. Int J STD AIDS 1991; 2:176-9.
55. Drummond F, Ryder N, Wand H, et al. Is azithromycin adequate treatment for asymptomatic rectal chlamydia? Int J STD AIDS 2011; 22:478-80.
56. Steedman NM, McMillan A. Treatment of asymptomatic rectal Chlamydia trachomatis: Is single-dose azithromycin effective? Int J STD AIDS 2009; 20:16-8.
57. Bernstein KT, Marcus JL, Nieri G, et al. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr 2010; 53:537-43.
58. Lanjouw E, Ossewaarde JM, Stary A, et al. 2010 European guideline for the management of Chlamydia trachomatis infections. Int J STD AIDS 2010; 21:729-37.